The DOI matches its Crossref record.
The Epidemiology of Antiretroviral Drug Resistance among Drug‐Naive HIV‐1–Infected Persons in 10 US Cities
Abstract
Background. The prevalence and characteristics of persons with newly diagnosed human immunodeficiency virus (HIV) infections with or without evidence of mutations associated with drug resistance have not been well described. Methods. Drug-naive persons in whom HIV had been diagnosed during the previous 12 months and who did not have acquired immune deficiency syndrome were sequentially enrolled from 39 clinics and testing sites in 10 US cities during 1997–2001. Genotyping was conducted from HIV-amplification products, by automated sequencing. For specimens identified as having mutations previously associated with reduced antiretroviral-drug susceptibility, phenotypic testing was performed. Results. Of 1311 eligible participants, 1082 (83%) were enrolled and successfully tested; 8.3% had reverse transcriptase or major protease mutations associated with reduced antiretroviral-drug susceptibility. The prevalence of these mutations was 11.6% among men who had sex with men but was only 6.1% and 4.7% among women and heterosexual men, respectively. The prevalence was 5.4% and 7.9% among African American and Hispanic participants, respectively, and was 13.0% among whites. Among persons whose sexual partners reportedly took antiretroviral medications, the prevalence was 15.2%. Conclusions. Depending on the characteristics of the patients tested, HIV-genotype testing prior to the initiation of therapy would identify a substantial number of infected persons with mutations associated with reduced antiretroviral-drug susceptibility. Antiretroviral-drug resistance is an important cause of treatment failure in persons infected with HIV-1 and has been associated with increased mortality [1-4]. Although the transmission of drug-resistant strains of HIV has been well documented [5], the prevalence and characteristics of persons with or without mutations associated with drug resistance are less clear. A number of studies have examined the prevalence of mutations associated with resistance in small samples of recently or acutely infected persons, mostly white men who have sex with men (MSM) [6-13]. Fewer studies have assessed the prevalence of mutations in drug-naive persons with newly diagnosed infections whose infections are, for the most part, of unknown duration; these persons are more typical of HIV-infected patients presenting for initial evaluation and treatment. In addition, few studies have been sufficiently large and representative of newly diagnosed HIV to describe the characteristics of persons infected with drug-resistant strains of HIV. A concern with testing chronically infected patients is that, even if drug-resistant mutations are initially present, in the absence of drug selection pressures, drug-resistant mutations may become undetectable if the infecting strains revert to wild type or become overgrown by fitter wild-type viruses; persisting as archived viruses or as minority species, they may not be detectable by current assays [14], even though they may become problematic with the introduction of therapy and selective pressures on the predominant wild-type strains. Consequently, resistance testing prior to initiation of antiretroviral therapy in persons with established HIV infection, although recommended by some when duration of infection or regional prevalence can be established [15], has not been widely recommended in the United States [16]. To describe the prevalence and characteristics of persons with mutations associated with reduced drug susceptibility, we systematically enrolled, in multiple venues across the United States, drug-naive persons in whom HIV infection had been recently diagnosed. As a better understanding of patterns of antiretroviral-drug resistance in persons presenting for care emerges, this kind of information may help to guide recommendations for baseline resistance testing and, possibly, the selection of initial antiretroviral regimens.> Patients. HIV- 1-infected persons in whom the condition had been diagnosed during the previous 12 months were enrolled consecutively from 39 selected HIV care clinics, HIV counseling and testing sites, and other clinical settings in 10 US cities during 1997-2001. Eligibility criteria included age ⩾18 years, antiretroviral-drug-naive status according to medical chart review (if a chart was available) and personal interview, and no history of AIDS-defining conditions (including a CD4+ T cell count <200 cells/mm3). After informed consent was obtained, demographic, risk-behavior, and clinical information was obtained from medical charts, if available, and from standardized interviews. Blood specimens were obtained from each consenting participant. The study was approved by the institutional review board at the Centers for Disease Control and Prevention and by the local human-subject review boards affiliated with the clinics or other sites where participants were enrolled. Resistance testing. Reverse transcriptase (RT) and protease genotyping was cond
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Markowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408
Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050158 · Cited by 371
Self-citationHIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
Shafer, R. W., Rhee, S.-Y., Pillay, D., Miller, V., Sandstrom, P., Schapiro, J. M., Kuritzkes, D. R., & Bennett, D. (2007) · AIDS · doi:10.1097/qad.0b013e328011e691 · Cited by 324
Self-citation
Metadata
- Authors
- Weinstock, H. S., Zaidi, I., Heneine, W., Bennett, D., Garcia‐Lerma, J. G., Douglas, Jr., LaLota, M., Dickinson, G., Schwarcz, S., Torian, L., Wendell, D., Paul, S., Goza, G. A., Ruiz, J., Boyett, B., & Kaplan, J. E.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-15
- Volume
- 189
- Issue
- 12
- Pages
- 2174-2180
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2122858451
- Cited by
- 246
- References
- 0
- FWCI
- 17.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Epidemiology of Antiretroviral Drug Resistance among Drug‐Naive HIV‐1–Infected Persons in 10 US Cities. https://app.cochat.ai/papers/10.1086/420789
- The paper
- Weinstock, H. S., Zaidi, I., Heneine, W., Bennett, D., Garcia‐Lerma, J. G., Douglas, Jr., LaLota, M., Dickinson, G., Schwarcz, S., Torian, L., Wendell, D., Paul, S., Goza, G. A., Ruiz, J., Boyett, B., & Kaplan, J. E. (2004). The Epidemiology of Antiretroviral Drug Resistance among Drug‐Naive HIV‐1–Infected Persons in 10 US Cities. The Journal of Infectious Diseases. https://doi.org/10.1086/420789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.